Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis

This RCT trial with 14 participants revealed well toleration of empagliflozin with improvement.

The study points include the following:

• There were 14 patients with SIAD aged 72 years who were predominantly females.
• The comparison was made for 4-week empagliflozin 25 mg/day to placebo.
• At baseline, the median serum sodium level was 131 mmol/L which rose to 134 mmol/L after treatment with empagliflozin.
• In the placebo, there no improvement was seen.
• Empagliflozin treatment improved neurocognition with an increase of 1.16 in the MoCA score.

The researchers reported no side effects. They wrote empagliflozin is a cost-effective treatment option Considering its cardiovascular and renal benefits.

It is beneficial in chronic hyponatremia with a high burden of comorbidities.

The study's strength includes study design and novelty approach whereas limitation include small sample size and possible power issue for detecting test performance difference.

References:

Refardt, Julie1,2; Imber, Cornelia1,2; Nobbenhuis, Rianne1,2; Sailer, Clara O.1,2; Haslbauer, Aaron3; Monnerat, Sophie1,2; Bathelt, Cemile1,2; Vogt, Deborah R.2; Berres, Manfred4; Winzeler, Bettina1,2; Bridenbaugh, Stephanie A.3; Christ-Crain, Mirjam1,2. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Journal of the American Society of Nephrology 34(2):p 322-332, February 2023. | DOI: 10.1681/ASN.2022050623